Exodus Point Capital Management, LP Myovant Sciences Ltd. Transaction History

Exodus Point Capital Management, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$11.6 - $20.44 $154,755 - $272,690	13,341 Added 19.08%	83,247 $1.5 Million
Q2 2022 Aug 19, 2022	BUY	$7.78 - $14.69 $374,933 - $707,940	48,192 Added 221.94%	69,906 $869,000
Q1 2022 May 13, 2022	SELL	$11.38 - $16.4 $5,291 - $7,625	-465 Reduced 2.1%	21,714 $289,000
Q4 2021 Feb 11, 2022	SELL	$14.31 - $23.87 $41,241 - $68,793	-2,882 Reduced 11.5%	22,179 $345,000
Q3 2021 Nov 15, 2021	SELL	$18.94 - $26.99 $3.44 Million - $4.9 Million	-181,717 Reduced 87.88%	25,061 $562,000
Q2 2021 Aug 16, 2021	BUY	$17.07 - $24.56 $3.53 Million - $5.08 Million	206,778 New	206,778 $4.71 Million
Q4 2020 Feb 16, 2021	SELL	$13.8 - $27.62 $557,851 - $1.12 Million	-40,424 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$14.05 - $22.6 $43,526 - $70,014	-3,098 Reduced 7.12%	40,424 $568,000
Q2 2020 Aug 14, 2020	BUY	$7.34 - $20.84 $319,451 - $906,998	43,522 New	43,522 $897,000
Q4 2019 Feb 14, 2020	SELL	$4.2 - $19.21 $52,920 - $242,046	-12,600 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.19 - $9.46 $65,394 - $119,196	12,600 New	12,600 $66,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.